MPM BioImpact
Impact investorBoston · Pre-Seed–Late Stage · 55 people tracked
Also known as MPM ASSET MANAGEMENT LLC · MPM Capital
Investment thesis
MPM BioImpact leverages three decades of biotech venture expertise combined with impact investing principles to support companies across all drug development phases. The firm invests in both private and public biotech companies that aim to meaningfully improve patient outcomes and transform treatment of disease, while maintaining commitment to global impact investment standards.
Source: firm website, verified Aug 25, 2026.
Team · 55 people
from the firm's website & public directories
Founder mafia
The MPM BioImpact mafia →11 people who came through MPM BioImpact went on to found or lead other companies.
What they invest in
from 42 of 52 portfolio companiesBiotech ×39Healthtech ×17Medical Devices ×8AI & Machine Learning ×6Deep Tech ×3Digital Health ×3Longevity ×2Consumer ×1
HQs:United States×39
Who they back
founder profiles across 11 portfolio companiesFounding team size:solo founder×52 founders×33 founders×24+ founders×1
Investments · showing 49 of 52
founders shown can be your intro pathBy year:2026 · 12025 · 32024 · 32022 · 12021 · 42020 · 42019 · 12018 · 42017 · 32016 · 32014 · 42012 · 132 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)
BoardHelen S. Kim(Director)Oleg Nodelman(Director)inAndrew Levin(Director)
Board seatTodd Foley· per SEC Form D
Co-investorsAndreessen HorowitzEcoR1 CapitalMRL Ventures FundRA CapitalTCG CrossoverVida Ventures+2 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatTodd Foley· per SEC Form D
Co-investors5AM VenturesRoche Venture FundTCG CrossoverAgent Capital
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)
BoardLawrence Klein, Ph.D.(Director)
Co-investorsAtlas VentureVida VenturesForbionHercules Capital, Inc.
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)
BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)John Hamer(Director)in
Board seatLuke Evnin· per SEC Form D
Co-investorsDCVC BioQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundDCVC (Data Collective)
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechHealthtechLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Co-investorsAvalon BioVenturesCatalys Pacific
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsDCVC BioLilly Asia VenturesVersant VenturesDCVC (Data Collective)
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)Edward Holson(Co-founder & CSO)Lizzie Ngo(Co-founder)David Steinberg(Chairman & Founding CEO)Brian Fenton(President & CEO)
Co-investorsLongwood Fund8VCMRL Ventures FundOno Venture Investment, Inc.
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)Courtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersAbingworthGilead SciencesAstellas Venture Management LLCLightstone Ventures
Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.
BiotechHealthtech
Anil Singhal(President and CEO)Siddhartha Mitra(Chief Medical Officer)
Co-investorsCanaan PartnersAstellas Venture Management LLCLightstone Ventures
BiotechSan Francisco, US
Jeanmarie Guenot(Executive Officer, Director)Florian Fischer(Director)
Board seatVinay BhaskarLuke Evnin· per SEC Form D · $7M raise · filed Jul 2017
Co-investorsQiming Healthcare
BiotechSan Diego, US
Daniela Salvemini(Director)Gary J. Bennett(Executive Officer, Director)
BoardEd Hurwitz(Director)in
Board seatGary Patou· per SEC Form D · $3.1M raise · filed Mar 2019
BiotechSouth San Francisco, US
Wendye Robbins(Executive Officer, Director)
BoardCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)
Board seatLuke Evnin· per SEC Form D · $50M raise · filed Oct 2019
Co-investorsBay City CapitalOUP (Osage University Partners)Pfizer Venture Investments+ND Capital
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)Todd T. Foley(Director)inVincent Miles(Director)
Board seatBard GeesamanDavid StackAnsbert K. Gadicke· per SEC Form D · $87.2M raise · filed Mar 2015
Co-investorsHEALTHCARE ROYALTY PARTNERSSofinnova Ventures
Digital data collection and clinical trial technology platform offering Direct Data Capture, eCOA, eConsent, and digital biomarkers.
Winston-Salem, US
Douglas E. Pierce, Jr.(Executive Officer, Director, Promoter)Joe Schmidt(Executive Officer)Edward S. Seguine(Executive Officer, Director, Promoter)
BoardAnsbert Gadicke(Director)inMatt King(Director)inBrad Geesaman(Director)
Board seatTony RosenbergTodd FoleyAnsbert K. Gadicke· per SEC Form D · $2.5M raise · filed Dec 2017
Co-investorsFCA Venture PartnersMcKesson Ventures
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Board seatTodd Foley· per SEC Form D
Co-investorsPfizer Venture InvestmentsPfizer VenturesPolaris PartnersTaiho Ventures, LLC
South San Francisco, US
Board seatTodd Foley· per SEC Form D · $72M raise · filed Mar 2024
Co-investorsVersant Ventures
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)Jim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)
Board seatLuke Evnin· per SEC Form D
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesRA CapitalDCVC BioDeerfield Management Company
BiotechSouth San Francisco, US
Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)
BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)
Board seatPatrick BaeuerleLuke EvninPablo CagnoniDan Hicklin· per SEC Form D · $70M raise · filed Nov 2018
Co-investorsK2 HealthVenturesTaiho Ventures, LLC
BiotechCambridge, US
Lloyd M. Segal(Director)
BoardBrian Goodman(Executive Officer)inMatthew Roden(Executive Officer, Director)
Board seatTodd Foley· per SEC Form D · $72M raise · filed Feb 2021
BiotechBrisbane, US
Hans Peter Gerber(Executive Officer, Director)
BoardChristopher Arendt(Director)Lori Kunkel(Director)
Board seatBard GeesamanDan HicklinLuke Evnin· per SEC Form D · $56M raise · filed Jan 2017
BiotechOklahoma City, US
Russell P. Rother(Executive Officer, Director, Promoter)Scott A. Rollins(Executive Officer, Director, Promoter)Philip Jones(Director)Richard Alvarez(Executive Officer)
BoardMichael Moradi-Araghi(Director)
Board seatTodd Foley· per SEC Form D · $15.6M raise · filed Oct 2025
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)Ivan Cheung(Chief Executive Officer)Leena Gandhi(Chief Medical Officer)Tatiana Novobrantseva(Chief Scientific Officer)Axel Hoos(Director)
Board seatDetlev Biniszkiewicz· per SEC Form D
Co-investorsCatalio Capital Management, LPSanofi VenturesCatalio Capital ManagementInvusLeaps by BayerSixty Degree Capital
Cambridge, US
Christophe Queva(Executive Officer)Theodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)
Board seatMitchell FinerLuke EvninBriggs Morrison· per SEC Form D · $89.6M raise · filed Dec 2019
Co-investorsAstellas Venture Management LLC
BiotechCambridge, US
Cynthia Seidel-Dugan(Executive Officer)David Cordo(Executive Officer)Daniel Hicklin(Executive Officer, Director)Reid Leonard(Executive Officer)
BoardArnold Oronsky(Director)
Board seatLuke Evnin· per SEC Form D · $38M raise · filed Mar 2016
Watertown, US
Board seatLuke Evnin· per SEC Form D · $76.9M raise · filed Jul 2023
Co-investorsAstellas Venture Management LLC
BiotechCambridge, US
BoardDetlev Biniszkiewicz(Executive Officer, Director)inEd Hurwitz(Director)in
Board seatBard Geesaman· per SEC Form D · $6.5M raise · filed Nov 2018
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)Gregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Board seatAnsbert K. Gadicke· per SEC Form D
Co-investorsFemHealth VenturesMitsui Global InvestmentNovo Holdings
BiotechOklahoma City, US
Scott Rollins, Ph.D.(Executive Officer, Director)David Facloner(Executive Officer)Richard Alvarez(Executive Officer)Rodger McEver, M.D.(Director)Russell Rother(Executive Officer)
Board seatTodd Foley· per SEC Form D · filed Dec 2020
BiotechCambridge, US
David Cordo(Executive Officer)Daniel Hicklin(Executive Officer, Director)
Board seatLuke Evnin· per SEC Form D · $1 raise · filed Dec 2016
Co-investorsAstellas Venture Management LLC
BiotechBoston, US
Daniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)
BoardArnold Oronsky(Director)Phil Gutry(Director)
Board seatLuke Evnin· per SEC Form D · $33M raise · filed Jan 2015
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Board seatLuke EvninBriggs Morrison· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundRA CapitalTaiho Ventures, LLC
Co-investorsNovartis Venture FundSV Health InvestorsUCL Technology Fund
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)John Sayward(Executive Officer)
Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersLumira VenturesOUP (Osage University Partners)Sofinnova Ventures+2 more
argenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies.
BiotechHealthtech
Co-investorsAvoro Capital AdvisorsPMV
āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers.
BiotechHealthtechBurlingame, US
Pankaj Bhargava(Founder & Chief Executive Officer)Victoria Smith(Chief Scientific Officer)Deborah Wenkert(Chief Medical Officer)Joseph Sarret(Acting Chief Operating Officer)Brian Shuster(Acting Chief Business Officer)
Co-investorsAgent Capital
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Co-investorsLAVLilly Asia VenturesSchooner CapitalTaiho Ventures, LLC
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)Mike Paglia(Chief Technology Officer)Ger Brophy(CEO)
Co-investorsEcoR1 CapitalSamsara BioCapitalSoftBank Vision Fund
Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development.
BiotechHealthtechMedical Devices
Scott Hirsch(CEO)Dan Kaplan(CSO)
Co-investorsDecheng Capital
K2 Space designs and builds satellite hardware and subsystems — including power, propulsion, autonomy, thermal, and structures — for space missions such as multi-orbit constellations, deep space relay, and large-scale observatories.
Deep TechHardwareSpace Tech
Karan Kunjur(CEO, Co-Founder)inNeel Kunjur(CTO, Co-Founder)
Co-investorsAlpine Space VenturesCapitalGFirst Round CapitalICONIQKleiner PerkinsPathbreaker Ventures+10 more
K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials.
BiotechHealthtech
HealthtechNewark, US
John Hendrick(Executive Officer, Director)Stephen Martin(Director)William Link(Director)Ryan Schwarz(Director)Steven Waite(Director)Andy Corley(Director)
Co-investorsSV Health InvestorsOxford Finance LLCSV Life SciencesVersant Ventures
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.
AI & Machine LearningBiotechMedical Devices
Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)
Co-investorsAstellas Venture Management LLCTaiho Ventures, LLC
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersVida Ventures+1 more
Co-investorsVida Ventures
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechMedical DevicesMenlo Park, US
Dr. Daniel J. Siegwart
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersOrbiMedOUP (Osage University Partners)Pfizer Venture Investments+6 more
Pioneering a new treatment paradigm for severe mental health disorders with rapid-acting and well-tolerated therapeutic options.
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
Co-investorsARCH Venture PartnersJDRF T1D FundSlater Technology FundEight Roads Ventures
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)Mitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsF-Prime Capital
An Italian-language affiliate guide that reviews and ranks non-AAMS online casinos (foreign-licensed gambling sites) accessible to Italian players, comparing bonuses, game catalogs, payment methods, and licensing.
ConsumerGamingMedia & EntertainmentBridgewater, US
William Duke(Executive Officer)Daniel Pelak(Director)Sean Traynor(Director)Steve LaPorte(Director)Paul Queally(Director)John Barr(Director)
Co-investorsAgate Medical Investments LPHLM Venture PartnersKaiser Permanente VenturesAbingworthPitangoWelsh, Carson, Anderson & Stowe
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioAktis OncologyNASDAQ: AKTSEntrada Therapeutics, Inc.NASDAQ: TRDADyne TherapeuticsNASDAQ: DYN
Portfolio news
latest coverage across their companies
Firefly · siliconangle.com · Aug 20, 2026
K2 · technode.global · Aug 12, 2026
ReCode Therapeutics · geekwire.com · Jul 13, 2026
Fable · bankinfosecurity.com · Jul 8, 2026
Dyne Therapeutics · intellectia.ai · Jul 1, 2026
Cullinan Oncology · investing.com · Jun 23, 2026
Frequently asked questions
- How many investments has MPM BioImpact made?
- MPM BioImpact has 27 tracked investments, including 3 dated in the last 24 months.
- What stage does MPM BioImpact invest at?
- MPM BioImpact invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is MPM BioImpact's typical check size?
- MPM BioImpact typically writes checks of $1M – $15M.
- What sectors does MPM BioImpact focus on?
- MPM BioImpact focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Mental Health.
- Where is MPM BioImpact located?
- MPM BioImpact is headquartered in Boston, US.
- Who does MPM BioImpact co-invest with?
- MPM BioImpact most often shares deals with Vida Ventures, Astellas Venture Management LLC, Canaan Partners, among 45 tracked co-investors.
Co-investors · 39
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
MRL Ventures Fund (MRLV) is the therapeutics-focused corporate venture group of MSD, backing early-stage, preclinical drug-development companies across all modalities with capital and scientific partnership.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
▶27 more co-investors
Polaris PartnersAtlas VentureARCH Venture PartnersOrbiMedDeerfield Management CompanyDigitalis VenturesLeaps by BayerNovo HoldingsCatalio Capital Management, LPGV (Google Ventures)Bessemer Venture PartnersNorwest Venture PartnersDraper Fisher Jurvetson (DFJ)Third Point VenturesEarlybird Venture CapitalSofinnova PartnersSR One Capital ManagementThe Column GroupFrazier Healthcare PartnersVivo CapitalQiming Venture PartnersTencent Holdings6 Dimensions CapitalCofounders CapitalMedical Excellence CapitalPureos BioventuresJMI Equity
Firms observed investing alongside MPM BioImpact, from public investor directories. Shared companies are the overlap with MPM BioImpact's recorded portfolio.
Similar investors
Equitage Ventures is an early-stage investor providing capital, distribution, and strategic guidance to entrepreneurs addressing the physical, mental, spiritual, and social needs of older adults across the senior care continuum.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Obvious is a venture capital firm focused on supporting founders building solutions to humanity's largest challenges across planetary health, human health, and economic health.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.